BioLineRx Ltd. (BLRX) CEO Phil Serlin on Q4 2020 Results - Earnings Call Transcript

BioLineRx Ltd. (NASDAQ:BLRX) Q4 2020 Earnings Conference Call February 23, 2021 10:00 AM ET

Company Participants

Timothy McCarthy - LifeSci Advisors
Phil Serlin - Chief Executive Officer
Mali Zeevi - Chief Financial Officer
Avi Vainstein - Chief Medical Officer
Ella Sorani - Chief Development Officer

Conference Call Participants

Joe Pantginis - HC Wainwright

Operator

Ladies and gentlemen, thank you for standing by. Welcome to the BioLine Rx Fourth Quarter and Full Year 2020 Results Conference Call. All participants are at present in a listen-only mode. Following the management's formal presentation, instructions will be given for the question and answer session [Operator Instruction].

I would now like to turn over the call to Timothy McCarthy of LifeSci Advisors to read the safe harbor statement, Tim, please go ahead.

Timothy McCarthy

Thank you, operator. Before turning the call over to management, I would like to make the following remarks concerning forward-looking statements. All statements in this conference call other than historical facts are indeed forward-looking statements. The words anticipate, believe, estimate, expect, intend, guidance, confidence, target, project and other similar expressions are used typically to identify such forward looking statements.

These forward looking statements are not guarantees of future performance and may involve and are subject to certain risks and uncertainties and other factors that may affect BioLineRx’s business, financial condition and other operating results. These include, but are not limited to, the risk factors and other qualifications contained in BioLineRx’s annual report on Form 20, quarterly reports filed in the 6K and other reports filed by BioLineRx with the SEC to which your attention is directed. Actual outcomes and results may differ materially from what is expressed or implied by these forward looking statements. BioLineRx expressly disclaims any intent or obligation to update these forward looking statements.

At this time, it is